Drug Trial Radar · NCT07434973
Stratification and Treatment in Early Psychosis Study - PROMOTE
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
586
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 1, 2029
Study completion Dec 1, 2031
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Wellcome Trust; Jazz Pharmaceuticals
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this trial is: * To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis. * To confirm the safety of CBD in individuals at clinical high risk for psychosis. The trial is a randomised, double-blind, placebo-controlled, multi-centre, international clinical trial. Individuals meeting clinical high risk for psychosis criteria will be recruited for the trial intervention component of the trial. Participants are randomised to treatment with oral CBD 300mg (oral solution 100 mg/mL) twice daily, or a matching placebo, for 104 weeks. By using a battery of clinical outcome assessments, the trial will be able to assess several biomarkers to predict clinical outcomes and response to treatment with CBD. Participants will be invited to provide blood samples, stool samples, cerebrospinal fluid samples (if aged 18 years or over) and complete neuroimaging assessments. Individuals who are not found to have mental illness as defined by DSM-5 criteria will be recruited to a healthy control group, to validate the biomarker component of the trial. Additionally, a control group of healthy volunteers will be recruited who will not take the trial intervention to aid calibration between datasets from sites acquiring MRI data and to inform and validate any possible multivariate signature associated with the CHR-P state, course or outcome by understanding how these measures are different in controls. Healthy controls will also be used for secondary case-control comparisons. Healthy controls will undergo clinical and biomarker assessments only.
Conditions
- Clinical High Risk for Psychosis (CHR)
- Clinical High Risk for Psychosis
- Clinical High Risk for Developing Psychosis
Interventions
Cannabidiol (CBD)Drug
CBD 100 mg/mL Oral Solution
PlaceboDrug
Placebo for Cannabidiol oral solution 100mg/mL oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- ChaChange from baseline in attenuated positive psychotic symptoms (CAARMS P1-P4 positive symptom subscale score)Time frame: Baseline to Week 104
Locations
19 sites in 10 countries. Site status is shown where the registry gives one.
MedUni Vienna, Department of Child and Adolescent Psychiatry
Vienna, Austria
Douglas Hospital Research Centre
Montreal, Canada
University Hospital Turku
Turku, Finland
Vivantes Network for Health GmbH
Berlin, Germany
University of Cologne, Faculty of Medicine and University Hospital of Cologne
Cologne, Germany
University Medical Center Schleswig-Holstein
Lübeck, Germany
Ludwig Maximilian University Hospital
München, Germany
National and Kapodistrian University of Athens
Athens, Greece
University of Bari Aldo Moro
Bari, Italy
University of Campania L. Vanvitelli
Naples, Italy
University of Pavia
Pavia, Italy
IRCCS Santa Lucia Foundation
Roma, Italy
Stichting Amsterdam UMC
Amsterdam, Netherlands
Biobizkaia Health Research Institute (Asociación Instituto de Investigación Sanitaria)
Bilbao, Spain
Foundation for Biomedical Research of the Gregorio Marañón Hospital (FIBHGM)
Madrid, Spain
Psychiatric University Hospital (PUK)
Zurich, Switzerland
Cambridgeshire and Peterborough NHS Foundation Trust
Cambridge, United Kingdom
Institute of Psychiatry, Psychology & Neuroscience, King's College London
London, United Kingdom
Oxford Health NHS Foundation Trust (OHFT)
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.